An internal standard for the quantification of captopril
Related Products
Unlabeled Version(s)
15313Captopril
Technical Support & Resources

Visit our FAQ

Contact Us

Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888

Request Technical Support

Technical Support Request

To streamline the process attach the appropriate questionnaire to your inquiry.

Download IHC QuestionnaireDownload WB Questionnaire

View Our Privacy Statement for details on how we use and protect your data. In addition, this site is protected by hCaptcha and its Privacy Policy and Terms of Service apply.

Captopril-d3

Item No. 25235

Product Insert (PDF)Safety Data Sheet (SDS) (PDF)
Technical Information
Formal Name
(S)-1-((S)-3-mercapto-2-methylpropanoyl)pyrrolidine-2-carboxylic-2,5,5-d3 acid
CAS Number
1356383-38-4
Molecular Formula
C9H12D3NO3S
Formula Weight
220.3
Purity
≥99% deuterated forms (d1-d3)
Formulation
A solid
Solubility(Learn about Variance in Solubility)
DMF: 30 mg/mlDMSO: 30 mg/mlEthanol: 30 mg/mlPBS (pH 7.2): 3 mg/ml
SMILES
OC([C@]1([2H])CCC([2H])([2H])N1C([C@H](C)CS)=O)=O
InChi Code
InChI=1S/C9H15NO3S/c1-6(5-14)8(11)10-4-2-3-7(10)9(12)13/h6-7,14H,2-5H2,1H3,(H,12,13)/t6-,7+/m1/s1/i4D2,7D
InChi Key
FAKRSMQSSFJEIM-SIHDFBQLSA-N
Shipping & Storage Information
Storage
-20°C
Shipping
Room temperature in continental US; may vary elsewhere
Recommended Products

Certificates of Analysis & Batch Specific Data

Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.

Download most recent Certificate of Analysis for this product

    100 µg

    $41

    Add

    250 µg

    $90

    Add

    500 µg

    $157

    Add
    Product Description

    Captopril-d3 is intended for use as an internal standard for the quantification of captopril (Item No. 15313) by GC- or LC-MS. Captopril is a first generation nonpeptidic ACE inhibitor (IC50 = 6.3 nM) that was designed based on bradykinin-potentiating peptides isolated from the venom of B. jararaca, a pit viper native to Brazil. 1,2,3 It does not exhibit a domain preference for binding either the C- or N-terminal active sites of the somatic form of ACE.1 Acute and chronic administration of captopril reduces blood pressure in spontaneously hypertensive Wistar-Kyoto rats and does not induce hypotension in salt-repleted normotensive Wistar-Kyoto rats.4 Captopril is also a competitive and reversible inhibitor of leukotriene (LTA4) hydrolase, which results in the disruption of LTB4 synthesis with an IC50 value of 14 μM.5

    WARNING This product is not for human or veterinary use.

    References & Product Citations
    Product Description References

    1. Dalkas, G.A., Marchand, D., Galleyrand, J.C., et al. Study of a lipophilic captopril analogue binding to angiotensin I converting enzyme. J. Pept. Sci. 16(2), 91-97 (2010).

    2. Redelinghuys, P., Nchinda, A.T., and Sturrock, E.D. Development of domain-selective angiotensin I-converting enzyme inhibitors. Ann. N. Y. Acad. Sci. 1056, 160-175 (2005).

    3. Cushman, D.W., and Ondetti, M.A. Design of angiotensin converting enzyme inhibitors. Nat. Med. 5(10), 1110-1113 (1999).

    4. Rubin, B., Antonaccio, M.J., and Horovitz, Z.P. Captopril (SQ 14,225) (D-3-mercapto-2-methylpropranoyl-L-proline): A novel orally active inhibitor of angiotensin-converting enzyme and antihypertensive agent. Prog. Cardiovasc. Dis. 21(3), 183-194 (1978).

    5. Orning, L., Krivi, G., Bild, G., et al. Inhibition of leukotriene A4 hydrolase/aminopeptidase by captopril. The Journal of Biological Chemisty 266(25), 16507-16511 (1991).